| DB ID | MyCo_2351 |
| Title | Soluble urokinase plasminogen activator receptor (suPAR) in bronchoalveolar fluid and blood in critically ill patients-a prospective cohort stud |
| Year | 2024 |
| PMID | 37973717 |
| Fungal Diseases involved | Fungal infection |
| Associated Medical Condition | critically ill patients |
| Genus | None |
| Species | None |
| Organism | None |
| Ethical Statement | The study protocol was approved by the Institutional Review Board of the Medical University of Graz, Austria (32-472 ex 19/20), registered in the WHO approved German study registry (DRKS00022458) and complied with the Dec- laration of Helsinki. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | suPAR |
| Biomarker Full Name | Soluble urokinase plasminogen activator receptor |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | In this study, we prospectively investigated concentrations of suPAR in BALF and serum in unselected adult critically ill patients who underwent bronchoscopy for any reason at the ICU of the Department of Internal Medicine at the Medical University of Graz, Austria. Seventy-five patients were available for analyses. Median age was 60. |
| Cohort No. | 75 |
| Age Group | 60 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | suPARnostic® ELISA Kit (ViroGates A/S, Copenhagen, Den-mark) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
